<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03420105</url>
  </required_header>
  <id_info>
    <org_study_id>PROSOM-K</org_study_id>
    <nct_id>NCT03420105</nct_id>
  </id_info>
  <brief_title>Study of the Functioning of Prospective Memory in Breast Cancer and the Influence of Sleep</brief_title>
  <acronym>PROSOM-K</acronym>
  <official_title>Study of the Functioning of Prospective Memory in Breast Cancer and the Influence of Sleep</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Francois Baclesse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Francois Baclesse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The results of this study will contribute to a better understanding of prospective memory
      deficit processes in breast cancer in relation to sleep disorders frequently reported in this
      pathology. In the long term, a better understanding will make it possible to envisage
      appropriate treatments to compensate for these memory difficulties and to improve the
      autonomy of the patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 5, 2018</start_date>
  <completion_date type="Anticipated">January 5, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 5, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>50 patients including:
25 patients being treated with adjuvant hormone therapy (Group A)
25 patients not receiving adjuvant hormone therapy (Group B)
25 healthy volunteers</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The memory components and memory loss mechanisms by questionnaires</measure>
    <time_frame>6 months after the end of radiotherapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The effect of sleep quality on the recovery of intentions in prospective memory by questionnaires</measure>
    <time_frame>6 months after the end of radiotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The impact of adjuvant hormone therapy on the functioning of prospective memory by questionnaires</measure>
    <time_frame>6 months after the end of radiotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The influence of anxio-depressive factors and fatigue on prospective memory by questionnaires</measure>
    <time_frame>6 months after the end of radiotherapy</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Memory Disorders</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients perform neuropsychological, psycho-pathological and quality of life assessments, and sleep tests</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients perform neuropsychological, psycho-pathological and quality of life assessments, and sleep tests</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Healthy volunteers perform neuropsychological, psycho-pathological and quality of life assessments, and sleep tests</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Neuropsychological, psycho-pathological and quality of life assessments</intervention_name>
    <description>Patients and Healthy volunteers perform neuropsychological, psycho-pathological and quality of life assessments, and sleep tests</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <other_name>sleep tests</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hormonotherapy</intervention_name>
    <description>Adjuvant hormone therapy</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Major patients under the age of 70;

          -  Patients who have been treated by surgery or radiotherapy for non-metastatic breast
             cancer

          -  Radiotherapy completed for about 6 months

          -  Level of study 3 &quot;end of primary studies&quot; minimum (Barbizet scale);

          -  French mother tongue;

          -  Menopausal women for at least 1 year before the selection visit

          -  Absence of primary cancer of the central nervous system or brain metastases;

          -  Absence of previous neurological damage;

          -  Absence of personality disorders and progressive psychiatric pathology;

          -  Having signed the informed consent to participate in the study.

        Exclusion Criteria:

          -  Primary cancer other than breast

          -  Metastatic cancer

          -  Treated by chemotherapy

          -  Cognitive function disorders pre-existing to cancer diagnosis

          -  Patients with paraneoplastic syndrome;

          -  Evolutionary psychiatric pathology;

          -  Refusal of participation;

          -  Patients unable to respond to cognitive tests;

          -  Drug use or excessive consumption of alcohol.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Florence JOLY, PhD</last_name>
    <phone>33 2 31 45 50 02</phone>
    <email>f.joly@baclesse.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jean-Michel GRELLARD</last_name>
    <phone>33 2 31 45 50 02</phone>
    <email>jm.grellard@baclesse.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florence JOLY, PhD</last_name>
      <phone>33 2 31 45 50 02</phone>
      <email>f.joly@baclesse.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Florence JOLY, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christelle LEVY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Djelila ALLOUACHE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emile GEORGE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ioana HRAB, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carine SEGURA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inserm-Ephe-Unicaen U1077 (</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2018</study_first_submitted>
  <study_first_submitted_qc>February 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2018</study_first_posted>
  <last_update_submitted>February 1, 2018</last_update_submitted>
  <last_update_submitted_qc>February 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Memory Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

